453 related articles for article (PubMed ID: 14567913)
1. TSH is a negative regulator of skeletal remodeling.
Abe E; Marians RC; Yu W; Wu XB; Ando T; Li Y; Iqbal J; Eldeiry L; Rajendren G; Blair HC; Davies TF; Zaidi M
Cell; 2003 Oct; 115(2):151-62. PubMed ID: 14567913
[TBL] [Abstract][Full Text] [Related]
2. TSH, the bone suppressing hormone.
Novack DV
Cell; 2003 Oct; 115(2):129-30. PubMed ID: 14567908
[TBL] [Abstract][Full Text] [Related]
3. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone.
Hase H; Ando T; Eldeiry L; Brebene A; Peng Y; Liu L; Amano H; Davies TF; Sun L; Zaidi M; Abe E
Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12849-54. PubMed ID: 16908863
[TBL] [Abstract][Full Text] [Related]
4. Genetic confirmation for a central role for TNFα in the direct action of thyroid stimulating hormone on the skeleton.
Sun L; Zhu LL; Lu P; Yuen T; Li J; Ma R; Baliram R; Moonga SS; Liu P; Zallone A; New MI; Davies TF; Zaidi M
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9891-6. PubMed ID: 23716650
[TBL] [Abstract][Full Text] [Related]
5. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass DA; Bialek P; Ahn JD; Starbuck M; Patel MS; Clevers H; Taketo MM; Long F; McMahon AP; Lang RA; Karsenty G
Dev Cell; 2005 May; 8(5):751-64. PubMed ID: 15866165
[TBL] [Abstract][Full Text] [Related]
6. A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism.
Bassett JH; Williams AJ; Murphy E; Boyde A; Howell PG; Swinhoe R; Archanco M; Flamant F; Samarut J; Costagliola S; Vassart G; Weiss RE; Refetoff S; Williams GR
Mol Endocrinol; 2008 Feb; 22(2):501-12. PubMed ID: 17932107
[TBL] [Abstract][Full Text] [Related]
7. TSH and bone loss.
Sun L; Davies TF; Blair HC; Abe E; Zaidi M
Ann N Y Acad Sci; 2006 Apr; 1068():309-18. PubMed ID: 16831931
[TBL] [Abstract][Full Text] [Related]
8. The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis.
Ma R; Morshed S; Latif R; Zaidi M; Davies TF
Thyroid; 2011 Aug; 21(8):897-906. PubMed ID: 21745106
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
10. [TSH affects bone metabolism. Surprising skeletal changes in genetically modified mice].
Lindstedt G
Lakartidningen; 2004 Feb; 101(6):476-7. PubMed ID: 15004943
[No Abstract] [Full Text] [Related]
11. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
Sampath TK; Simic P; Sendak R; Draca N; Bowe AE; O'Brien S; Schiavi SC; McPherson JM; Vukicevic S
J Bone Miner Res; 2007 Jun; 22(6):849-59. PubMed ID: 17352644
[TBL] [Abstract][Full Text] [Related]
12. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
13. Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation.
Zhang W; Zhang Y; Liu Y; Wang J; Gao L; Yu C; Yan H; Zhao J; Xu J
J Biomech; 2014 Apr; 47(6):1307-14. PubMed ID: 24629929
[TBL] [Abstract][Full Text] [Related]
14. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
15. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
[TBL] [Abstract][Full Text] [Related]
16. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
17. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
Ueland T; Bollerslev J; Mosekilde L
Ugeskr Laeger; 2002 Jul; 164(27):3526-30. PubMed ID: 12116680
[TBL] [Abstract][Full Text] [Related]
18. Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures.
Baliram R; Latif R; Berkowitz J; Frid S; Colaianni G; Sun L; Zaidi M; Davies TF
Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16277-82. PubMed ID: 21911383
[TBL] [Abstract][Full Text] [Related]
19. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
20. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
